GET DAILY SIGNALSWhy Is Turning Point Brands (TPB) Stock Down -0.36% Today?
Key Takeaways
- Turning Point Brands (TPB) is down about 0.36% today, trading near $58.60 versus a prior close of $58.81, extending a sharp multi-session selloff.
- The dominant catalyst remains the company's third-quarter 2026 results, which showed revenue growth but a steep decline in profitability driven by heavy marketing spend on its FRE and ALP nicotine pouches.
- Net income fell 81% year over year to $3.9 million, and adjusted EBITDA dropped 41% to $18.4 million, even as net sales rose 27% to $151.1 million.
- Analyst reaction has added pressure, with Needham lowering its price target to $95 from $125 while maintaining a Buy rating.
- The move appears stock-specific rather than sector-driven, with the shares down roughly 16% over the past week and trading near their 52-week low.
- For deeper detail on this name, explore Price Targets, Earnings, and Forecast pages to track valuation, upcoming results, and forward estimates.
- To discover AI-driven trading strategies active in today's market, explore Trending AI Robots.
Opening Summary
TPB, or Turning Point Brands, Inc., is a Louisville, Kentucky-based manufacturer and marketer of branded consumer products spanning the Zig-Zag rolling-paper franchise, Stoker's moist snuff and loose-leaf tobacco, and the fast-growing FRE and ALP modern oral nicotine pouch brands. In today's session, the stock is trading modestly lower, down about 0.36% to roughly $58.60 from a prior close of $58.81, as the shares consolidate near multi-month lows following a bruising post-earnings stretch. The market continues to weigh a third-quarter report that showed robust top-line momentum but a steep erosion in profitability.
Earnings Results Pressure Profitability
The core driver behind the stock's weakness is the company's third-quarter 2026 results, released on November 9. Net sales climbed 27% year over year to $151.1 million, and adjusted earnings per share of $0.41 topped consensus estimates. Yet the headline beat masked a sharp deterioration in the bottom line: GAAP net income plunged 81% to $3.9 million, and adjusted EBITDA fell 41% to $18.4 million.
The culprit was a surge in spending. Selling, general, and administrative expenses jumped 69% to $75.3 million as management invested aggressively in sales and marketing to expand distribution for its FRE and ALP nicotine pouches. While Modern Oral net sales more than doubled, rising 103% to $74.4 million and reaching 49% of total company sales, investors have grown wary of the cost of that growth and the timing of any payoff. The legacy Zig-Zag segment also weakened, with net sales down 15.5% to $37.3 million, compounding concerns.
Analyst Price Target Reduction
The earnings-driven slide was reinforced by analyst reaction. Needham lowered its price target on the stock to $95 from $125 while retaining a Buy rating, signaling that the path to margin recovery is now viewed as longer and more uncertain than previously expected. The revised target reflects both the heavier near-term investment in the nicotine pouch category and a push-out of the company's domestic manufacturing timeline, which management now expects to begin in 2027 pending FDA PMTA approvals. The combination of falling profits and a delayed infrastructure rollout has weighed on investor sentiment.
Market Context and Trading Activity
The decline in TPB has been largely stock-specific rather than a reflection of broad weakness in the consumer staples or tobacco sector. Trading volume picked up meaningfully during the sharpest down days, exceeding the stock's roughly 376,000-share average, consistent with institutional repositioning following the earnings reset. On a technical basis, the shares now sit well below both their 50-day and 200-day moving averages and are hovering near their 52-week low, underscoring the depth of the repricing from earlier highs.
What Comes Next for TPB
Looking ahead, traders will focus on whether management can translate its distribution wins into improved profitability. The company reaffirmed full-year 2026 guidance for Modern Oral gross sales of $330 million to $350 million and adjusted EBITDA of $70 million to $80 million, but the implied fourth-quarter sequential trajectory leaves limited room for error. Key watchpoints include the pace of chain-store expansion, the timing of FDA PMTA decisions that would unlock domestic manufacturing, and any evidence that marketing spend is moderating. Risks remain centered on margin compression, competition from established pouch incumbents, and the execution of a capital-intensive growth strategy.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that have demonstrated strength under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. Because only the strongest performers are featured in this section, the page can be a useful starting point for traders seeking systematic, data-driven ideas. Explore the Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TPB in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026
The 10-day moving average for TPB crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TPB's RSI Oscillator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +5.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where TPB advanced for three days, in 231 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
TPB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 166 of 222 cases where TPB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TPB as a result. In 50 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for TPB turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
TPB moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TPB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. TPB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.071) is normal, around the industry mean (-7.297). P/E Ratio (28.154) is within average values for comparable stocks, (12.512). Projected Growth (PEG Ratio) (0.048) is also within normal values, averaging (3.595). Dividend Yield (0.005) settles around the average of (0.060) among similar stocks. P/S Ratio (2.701) is also within normal values, averaging (2.780).
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 70, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of tobacco products
Industry Tobacco
Advertisement